证券代码：600671 证券简称：天目药业 公告编号：临 2025-049 杭州天目山药业股份有限公司 关于子公司取得换发后的《药品生产许可证》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州天目山药业股份有限公司（以下简称"公司"）获悉，公司全资子公 司黄山市天目药业有限公司（以下简称"黄山天目"）于近日收到安徽省药品 监督管理局换发的《药品生产许可证》（许可证编号：皖 20160182），换发后 的《药品生产许可证》有效期至 2030 年 12 月 31 日，具体情况如下： 一、《药品生产许可证》的主要信息 企业名称：黄山市天目药业有限公司 许可证编号：皖 20160182 社会信用代码：91341000151488891C 分类码：Ahz 注册地址：安徽省黄山市黄山经济开发区翰林路 7 号 有效期至：2030 年 12 月 31 日 生产地址和生产范围： 安徽省黄山市黄山经济开发区翰林路 7 号：硬胶囊剂，口服液，糖浆剂， 片剂，颗粒剂，丸剂（水蜜丸、浓缩丸、水丸）*** 二、对公司的影响 1 本次换发《药品 ...

Core Viewpoint - Tianmu Pharmaceutical's subsidiary has received a renewed drug production license, ensuring its normal operations without significant impact on the company's performance [1] Group 1 - Tianmu Pharmaceutical's wholly-owned subsidiary, Huangshan Tianmu Pharmaceutical Co., Ltd., has been issued a new drug production license by the Anhui Provincial Drug Administration [1] - The license number is皖20160182 and is valid until December 31, 2030 [1] - The renewal of the license guarantees the normal production and operation of the subsidiary [1]

Core Viewpoint - Tianmu Pharmaceutical has shown significant improvement in financial performance for the first three quarters of 2025, with a revenue increase of 27.48% year-on-year and a net profit of 14.21 million yuan, indicating a turnaround from previous losses and ongoing operational enhancements [1][2]. Financial Performance - The company achieved a revenue of 159 million yuan in the first three quarters, reflecting a 27.48% increase compared to the same period last year, driven by the steady recovery of core business and deepening market channel development [2]. - The net profit attributable to shareholders reached 14.21 million yuan, a significant improvement from a loss of 3.70 million yuan in the previous year, indicating enhanced profitability and financial structure optimization [2]. - The equity attributable to shareholders increased by 27.12% year-to-date, reaching 666 million yuan, showcasing the positive impact of the state-owned capital entry in Qingdao [2]. Asset and Investment - As of the end of the reporting period, the total assets of Tianmu Pharmaceutical stood at 430 million yuan, remaining stable compared to the beginning of the year [3]. - The company's construction in progress increased nearly 9.6 times year-on-year to 13.25 million yuan, primarily due to increased investment in the Huangshan Tianmu technology transformation project, indicating accelerated capacity upgrades and technological improvements [3]. Strategic Initiatives - Tianmu Pharmaceutical is advancing the Huangshan Tianmu technology transformation project with a total investment expected to reach 100 million yuan, aiming for production by the end of 2026, which will significantly enhance the extraction capacity and production efficiency of traditional Chinese medicine [4]. - The management has emphasized a focus on three main sectors: traditional Chinese medicine manufacturing, pharmaceutical distribution, and health, while continuing product innovation and resumption of production [4]. - The company has received re-registration approval for 53 drugs, surpassing the total for the entire year of 2024, with successful progress on key products like the pearl eye drops and the launch of extended products in the Tiepi Fengdou series, contributing to long-term growth potential [4]. Industry Outlook - The industry is witnessing a gradual recovery supported by increasing government policy backing for traditional Chinese medicine, with Tianmu Pharmaceutical positioned to benefit from product restructuring and channel optimization [4]. - The company is transitioning from "recovery growth" to "steady quality improvement," laying a solid foundation for sustained growth through optimized industrial layout, strengthened marketing networks, and enhanced governance structures [4].

Core Insights - Tianmu Pharmaceutical (600671.SH) reported a total operating revenue of 159 million yuan for the first three quarters of 2025, representing a year-on-year increase of 27.48% [1] - The net profit attributable to shareholders of the parent company reached 14.21 million yuan, a significant turnaround from a loss of 3.70 million yuan in the same period last year [1] - The basic earnings per share stood at 0.1167 yuan [1]

证券代码：600671 证券简称：天目药业 公告编号：临 2025-048 杭州天目山药业股份有限公司 关于子公司原房屋租赁合同终止及签署新合同 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 杭州天目山药业股份有限公司（以下简称"公司"）控股子公司青岛模 拟医学科技有限公司（以下简称"模拟医学"或者"老模拟"）因经营 调整需要，经与青岛源嘉润物实业有限公司（以下简称"源嘉润物"） 友好协商，提前终止原办公场地的租赁，双方签署《办公场地租赁合同 解除协议》（以下简称"《补充协议》"）。原合同自 2024 年 9 月 7 日至 2027 年 9 月 6 日止，经协商，原租赁合同提前至 2025 年 10 月 27 日终止。 公司全资子公司青岛模拟医学中心有限公司（以下简称"模拟医学中心" 或"新模拟"）为满足生产经营需要，拟租赁源嘉润物位于青岛市崂山 区九水东路 603 号的源嘉生命科技产业园 A#楼 1-3 层房屋用于运营、办 公，租赁面积约为 7,862.71 ㎡，租赁期限 1 年，自 20 ...

证券代码：600671 证券简称：天目药业 公告编号：临 2025-047 杭州天目山药业股份有限公司 第十二届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 杭州天目山药业股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日以 现场结合通讯表决方式召开了第十二届董事会第十六次会议。本次会议通知及会 议材料于 2025 年 10 月 24 日以电子或书面的方式送达各位董事。本次会议应出 席董事 8 名，实际出席董事 8 名。会议由董事长刘加勇先生主持，公司高级管理 人员列席会议。本次会议的召开符合《公司法》和《公司章程》的有关规定。本 次会议审议情况如下： 租赁，模拟医学拟与源嘉润物签署《办公场地租赁合同解除协议》（以下简称"《解 除协议》"）。原合同自 2024 年 9 月 7 日至 2027 年 9 月 6 日止，经协商同意，原 租赁合同提前至 2025 年 10 月 27 日终止。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn） ...

Financial Performance - The company's operating revenue for the third quarter was ¥55,343,038.75, a decrease of 15.03% compared to the same period last year[4]. - The total profit for the quarter was ¥2,882,447.89, reflecting a significant decline of 83.76% year-over-year[4]. - The net profit attributable to shareholders was ¥3,960,987.86, down 73.25% from the previous year[4]. - Basic earnings per share were ¥0.03, a decrease of 72.94% compared to the same period last year[5]. - Total operating revenue for the first three quarters of 2025 reached ¥158,940,412.66, a 27.5% increase from ¥124,680,446.71 in the same period of 2024[22]. - Operating profit for the first three quarters of 2025 was ¥7,153,523.96, compared to an operating loss of ¥7,305,559.19 in the first three quarters of 2024[22]. - Net profit for the first three quarters of 2025 was ¥7,508,073.79, a significant recovery from a net loss of ¥3,761,066.17 in the same period of 2024[23]. - The company reported a basic and diluted earnings per share of ¥0.1167 for the first three quarters of 2025, recovering from a loss of ¥0.0303 per share in the same period of 2024[23]. - The total comprehensive income attributable to the parent company for the first three quarters of 2025 was ¥14,208,796.60, compared to a loss of ¥3,695,546.06 in the same period of 2024[23]. Cash Flow - The cash flow from operating activities was negative at -¥19,958,994.53, indicating cash outflows during the quarter[4]. - Cash flow from operating activities showed a net outflow of ¥30,831,088.80 in the first three quarters of 2025, an improvement from a net outflow of ¥38,957,059.21 in the same period of 2024[25]. - Cash flow from investing activities resulted in a net outflow of ¥26,636,693.31 for the first three quarters of 2025, compared to a net outflow of ¥18,571,079.09 in the same period of 2024[26]. - Cash flow from financing activities generated a net inflow of ¥16,102,282.69 in the first three quarters of 2025, contrasting with a net outflow of ¥25,932,182.68 in the same period of 2024[26]. - The company's cash and cash equivalents were RMB 11,740,346.34, down from RMB 65,724,985.87 at the end of 2024[16]. - The company’s cash and cash equivalents at the end of the first three quarters of 2025 stood at ¥6,098,492.05, down from ¥14,502,291.44 at the end of the same period in 2024[26]. Assets and Liabilities - Total assets at the end of the reporting period were ¥429,727,307.20, a decrease of 2.66% from the end of the previous year[5]. - The net assets attributable to shareholders increased by 27.12% to ¥66,592,681.40 compared to the previous year-end[5]. - The company's total current assets amounted to RMB 220,539,380.50, a slight decrease from RMB 222,713,693.72 at the end of 2024[16]. - Total liabilities decreased to RMB 335,430,332.10 from RMB 356,444,336.38, a reduction of approximately 5.9%[18]. - The company's total equity increased to RMB 94,296,975.10 from RMB 85,018,901.31, representing a growth of about 10.4%[18]. - Non-current liabilities due within one year decreased by 4.102 million due to lease payments and the termination of lease agreements[9]. Receivables and Inventory - The company reported a significant increase in accounts receivable by 58.26%, primarily due to increases from subsidiaries[8]. - Accounts receivable increased to RMB 152,820,152.54 from RMB 96,565,118.72 at the end of 2024, indicating a growth of approximately 58.4%[16]. - Inventory decreased to RMB 41,498,781.04 from RMB 52,323,040.59, reflecting a decline of about 20.7%[16]. - Other receivables decreased by 710,000 compared to the end of last year, totaling -34.79 million[9]. - Other current assets increased by 2.4 million compared to the end of last year, totaling 121.88 million[9]. - Construction in progress increased by 11.96 million compared to the end of last year, totaling 957.40 million[9]. Expenses and Losses - Non-operating income and expenses resulted in a net loss of -¥1,018,712.99 for the period[7]. - Sales expenses increased by 1.27 million compared to the same period last year, totaling 127.68 million[10]. - Investment income decreased by 8.615 million due to the absence of related matters this year[9]. - Asset impairment losses increased by 6.2351 million compared to the same period last year[9]. - The company reported a net loss of RMB 242,155,533.95 in retained earnings as of September 30, 2025, compared to a loss of RMB 256,364,330.55 at the end of 2024[18]. Corporate Developments - The company established a wholly-owned subsidiary, Qingdao Simulation Medical Center, with a registered capital of RMB 3 million[14]. - The company wrote off inventory with a book value of RMB 3,092,147.88, including a provision for impairment of RMB 628,850.52[14]. Accounting Standards - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the year of first implementation[27].

Group 1 - The core viewpoint of the news is that Tianmu Pharmaceutical's stock has experienced significant fluctuations, with a year-to-date increase of 115.15% and recent trading activity indicating a mixed sentiment among investors [1][2] - As of October 27, Tianmu Pharmaceutical's stock price was 18.89 CNY per share, with a market capitalization of 2.3 billion CNY and a trading volume of 22.31 million CNY [1] - The company has seen a net inflow of 342,900 CNY from major funds, with large orders accounting for 17.90% of total buying and 16.36% of total selling [1] Group 2 - Tianmu Pharmaceutical's main business segments include health products (48.01%), circulation goods (23.21%), raw materials (15.98%), traditional Chinese medicine (11.47%), Western medicine (0.89%), training (0.32%), and other (0.12%) [1] - The company belongs to the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector, and is associated with concepts such as shell resources and small-cap stocks [2] - For the first half of 2025, Tianmu Pharmaceutical reported a revenue of 10.4 million CNY, representing a year-on-year growth of 73.97%, and a net profit attributable to shareholders of 10.25 million CNY, up 155.39% year-on-year [2] Group 3 - Since its A-share listing, Tianmu Pharmaceutical has distributed a total of 59.63 million CNY in dividends, with no dividends paid in the last three years [3]

Core Viewpoint - Tianmu Pharmaceutical's stock has experienced significant fluctuations, with a year-to-date increase of 111.05%, but a recent decline of 4.63% over the past five trading days [1][2]. Financial Performance - For the first half of 2025, Tianmu Pharmaceutical achieved operating revenue of 104 million yuan, representing a year-on-year growth of 73.97%. The net profit attributable to the parent company was 10.25 million yuan, reflecting a year-on-year increase of 155.39% [2]. Stock Market Activity - As of October 23, Tianmu Pharmaceutical's stock price was 18.53 yuan per share, with a market capitalization of 2.257 billion yuan. The stock saw a trading volume of 36.016 million yuan and a turnover rate of 1.58% [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on August 21, where it recorded a net buy of -55.03 million yuan [1]. Shareholder Information - As of September 19, the number of shareholders for Tianmu Pharmaceutical was 10,400, an increase of 3.21% from the previous period. The average number of circulating shares per shareholder was 11,690, a decrease of 3.11% [2]. Business Overview - Tianmu Pharmaceutical, established on June 1, 1992, and listed on August 23, 1993, is located in Hangzhou, Zhejiang Province. The company's main business includes pharmaceutical manufacturing, drug distribution, and traditional Chinese medicine diagnosis and treatment. The revenue composition is as follows: health products 48.01%, circulating goods 23.21%, raw materials 15.98%, traditional Chinese medicine 11.47%, Western medicine 0.89%, training 0.32%, and others 0.12% [1][2]. Dividend Information - Since its A-share listing, Tianmu Pharmaceutical has distributed a total of 59.6313 million yuan in dividends, with no dividends paid in the last three years [3].

Market Overview - On October 17, the traditional Chinese medicine sector declined by 0.99%, with Tianmu Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Notable gainers in the traditional Chinese medicine sector included: - Weikang Pharmaceutical: closed at 23.39, up 3.54% with a trading volume of 84,100 shares and a turnover of 26.66 million [1] - Enwei Pharmaceutical: closed at 31.40, up 2.45% with a trading volume of 24,700 shares and a turnover of 78.62 million [1] - Zhongsheng Pharmaceutical: closed at 17.45, up 2.11% with a trading volume of 706,300 shares and a turnover of 1.244 billion [1] - Major decliners included: - Tianmu Pharmaceutical: closed at 18.40, down 5.30% with a trading volume of 120,100 shares and a turnover of 22 million [2] - Jilin Aodong: closed at 20.23, down 3.39% with a trading volume of 226,500 shares and a turnover of 465 million [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 736 million from institutional investors, while retail investors saw a net inflow of 582 million [2][3] - Key stocks with significant capital flow included: - Zhongsheng Pharmaceutical: net inflow of 72.58 million from institutional investors, but a net outflow of 131 million from retail investors [3] - Tianmu Pharmaceutical: net inflow of 19.99 million from institutional investors, with net outflows from both retail and speculative investors [3]